- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07940829
A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment
A Pharmacokinetic Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment
This study is a single-center, single-dose, open-label study designed to evaluate the pharmacokinetic (PK) profile of RSS0343 tablets in healthy participants and in participants with mild or moderate renal impairment.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Ruifang Guan
- Telefonnummer: +86-518-82342973
- E-Mail: ruifang.guan.rg1@hengrui.com
Studieren Sie die Kontaktsicherung
- Name: Hongda Lin
- Telefonnummer: +86-518-82342973
- E-Mail: hongda.lin@hengrui.com
Studienorte
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Hauptermittler:
- Youhong Hu
-
Hauptermittler:
- Zhanzheng Zhao
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants voluntarily sign the informed consent form (ICF), have a full understanding of the purpose and significance of this study, and are willing to comply with the study protocol.
- Males or females aged 18 to 65 years (both boundaries inclusive).
- Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) = weight (kg) / height² (m²), with BMI within the range of 19 to 28 kg/m² (both boundaries inclusive).
- The absolute value of estimated glomerular filtration rate (eGFR) shall be calculated using the Modification of Diet in Renal Disease (MDRD) equation modified for the Chinese population (for the equation and calculation method). Participants with mild renal impairment: absolute eGFR of 60-89 mL/min; participants with moderate renal impairment: absolute eGFR of 30-59 mL/min (boundary values inclusive); healthy participants: absolute eGFR ≥ 90 mL/min and < 130 mL/min.
- Male and female participants of reproductive / childbearing potential and their partners must have no plan for pregnancy or for sperm / oocyte donation within 6 months (female participants) or 3 months (male participants) after the last dose, and must be willing to use highly effective contraceptive measures. Female participants of childbearing potential must have a negative serum pregnancy test prior to the first dose and must not be breastfeeding.
- (For participants with renal impairment, the following additional inclusion criteria must also be met) The participant has been diagnosed with chronic (> 3 months) and stable renal injury (no acute exacerbation due to deterioration of renal function within 1 month prior to screening), and medical records or laboratory reports confirming the diagnosis of renal impairment for more than 3 months must be provided.
- (Participants with normal renal function) Physical examination, 12-lead electrocardiogram (12-ECG), vital signs, chest imaging, abdominal ultrasonography (color Doppler ultrasound) and laboratory tests at screening and baseline are normal, or abnormal without clinical significance.
Exclusion Criteria:
-
Those who smoked more than 5 cigarettes per day (or used an equivalent amount of other nicotine-containing products) within 3 months prior to screening, or who plan to use any tobacco products during the study.
-
Regular alcohol drinkers within 6 months prior to screening (i.e., daily alcohol intake exceeding 15 g for females and 25 g for males [5 g of alcohol is equivalent to 150 mL of beer, 50 mL of wine, or approximately 17 mL of low-alcohol liquor], on more than 2 occasions per week) who are unable to abstain from any alcohol-containing products during the study; or those with a positive alcohol breath test at baseline.
-
Those with a history of drug abuse, illicit drug use, or drug dependence (as determined by interview/medical history), or a positive urine drug screen at baseline.
-
Blood donation or blood loss of ≥ 200 mL in total within 1 month prior to dosing, or ≥ 400 mL in total within 3 months prior to dosing; receipt of a blood transfusion within 8 weeks prior to dosing; difficult venipuncture, or a physical condition that cannot tolerate intensive blood collection.
-
Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), syphilis antibody, or human immunodeficiency virus (HIV) antibody.
-
Suspected allergy / hypersensitivity to the investigational product or any of its components, or a history of severe allergy to any drug, food, toxin, or other exposure.
-
Any surgery within 3 months prior to screening, or incomplete recovery from surgery as judged by the investigator, or any surgery planned during the study period through 1 month after the end of the study.
-
Participants who refuse to abstain from any methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, chocolate) from 48 hours prior to baseline until the end of the study; who refuse to abstain from any grapefruit-containing beverages or foods from 7 days prior to baseline until the end of the study; or who have special dietary requirements and are unable to comply with the standardized diet provided in the study.
-
Receipt of any live vaccine or live-attenuated vaccine within 1 month prior to screening, or a requirement for vaccination with a live vaccine during study participation (including within 30 days after the last dose of the investigational product).
-
Those who have participated in any clinical trials involving drugs or medical devices within three months prior to signing the informed consent form (or within five elimination half-lives of the studied drug, whichever is the longer period), excluding those who participated in other clinical trials but were not administered the drug due to screening failure.
Exclusion criteria for participants with renal dysfunction:
-
According to the judgment of the researchers, participants with renal dysfunction who are not suitable to participate in the study (such as those who have undergone kidney transplantation, those with urinary incontinence or anuria).
-
Those who, in the investigator's judgment, have experienced marked fluctuation or rapid deterioration of renal function within 2 weeks prior to dosing.
-
Those who have received renal replacement therapy (e.g., hemodialysis) within 3 months prior to screening, or who are expected to receive renal replacement therapy during the study.
-
Those with underlying diseases contributing to chronic kidney disease (e.g., diabetes mellitus, hypertension) that have been poorly controlled within 3 months prior to screening, as judged by the investigator.
-
Other than the primary renal disease itself, any history of serious disease, or any medical history and/or clinically significant abnormal clinical laboratory findings that, in the investigator's opinion, may affect the study results, including but not limited to a history of diseases of the circulatory, endocrine, nervous or digestive systems, or hematologic, immune, psychiatric or metabolic diseases.
-
Use of any prescription drugs, over-the-counter (OTC) drugs, Chinese patent medicines or dietary supplements, other than those used for the treatment of renal impairment and other concomitant diseases, within 2 weeks prior to administration of the study drug; or use of strong inhibitors or inducers of CYP3A4 and/or P-glycoprotein (P-gp) within 2 weeks prior to administration of the study drug.
Exclusion criteria for participants with normal renal function:
-
Previous severe primary diseases of important organs, including but not limited to gastrointestinal, respiratory, renal, liver, nervous, hematological, endocrine, tumor, immune, mental or cardiovascular and cerebrovascular diseases.
-
Use of any medication (including prescription drugs, over-the-counter drugs, herbal medicines, Chinese patent medicines, and dietary supplements) within 4 weeks prior to screening, or still within 5 half-lives of a drug at the time of screening (whichever is longer).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: RSS0343 Tablet Group
Administration of RSS0343 tablet. |
RSS0343 tablet, oral. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The maximum plasma concentration (Cmax)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
The area under the blood drug concentration-time curve from Time 0 to the last quantifiable concentration time (AUC0-t)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
The area under the blood drug concentration-time curve from Time 0 to the extrapolated infinite time (AUC0-inf)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to maximum plasma concentration (Tmax)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Terminal half-life (t1/2)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Apparent clearance (CL/F)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Apparent volume of distribution (Vz/F)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Cumulative amount of drug excreted unchanged in urine (Ae)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Fraction of the administered dose excreted unchanged in urine (Fe)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Renal clearance (CLr)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Plasma protein binding (PPB)
Zeitfenster: Day 1 - Day 12.
|
The PK Parameter. |
Day 1 - Day 12.
|
|
Incidence and severity of adverse events (AEs)
Zeitfenster: Day 1 - Day 12.
|
Safety Parameter. |
Day 1 - Day 12.
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- RSS0343-105
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .